Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour

Emma Di Carlo, Andrea Modesti, Anna Coletti, Mario P. Colombo, Mirella Giovarelli, Guido Forni, Maria G. Diodoro, Piero Musiani

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Injection of interleukin-4 (IL4) gene-transduced tumour cells into syngeneic immunocompetent mice resulted in turnout rejection in which a key role for eosinophils was suggested. To evaluate whether IL5 inhibits turnout growth by selectively inducing eosinophil recruitment and activation, a poorly differentiated mammary adenocarcinoma cell line (TSA) was transfected with the IL5 gene and the cells secreting IL5 (TSA-IL5) were injected subcutaneously (s.c,) in syngeneic mice. The oncogenicity of TSA-IL5 was compared with that exhibited by TSA cells transfected with the IL4 gene (TSA- IL4) and with the neomycin resistance gene only (TSA-neo). At progressive times after subcutaneous challenge, tumour growth areas were studied histologically, ultrastructurally, and immunohistochemically to identify the reactive cells, visualize tumour vessels, and detect the cytokines and chemokines involved in the anti-tumour reaction. Both the morphological and the functional data showed that TSA-IL5, despite the large eosinophil infiltrate, grew progressively like TSA-neo, suggesting that eosinophils per se do not play a crucial role in TSA tumour rejection. Furthermore, our data indicate that the rejection of TSA-IL4 depends on the IL4-induced expression of VCAM-1 and MCP-1 by endothelial cells. MCP-1 together with VCAM-1 results in recruitment and activation of basophils, mast cells, and macrophages, and hence a pro-inflammatory cytokine cascade that initially favours the influx and activation of neutrophils and finally tumour rejection. In this context, the rejection of TSA-IL4 seems to involve a variety of reactive cells and rests on a continuous cross-talk between basophils, mast cells, macrophages, CD8-positive lymphocytes, and granulocyte subsets, mostly neutrophils.

Original languageEnglish
Pages (from-to)390-397
Number of pages8
JournalJournal of Pathology
Volume186
Issue number4
DOIs
Publication statusPublished - 1998

Fingerprint

Interleukin-5
Interleukin-4
Endothelial Cells
Cytokines
Eosinophils
Neoplasms
Basophils
Vascular Cell Adhesion Molecule-1
Mast Cells
Genes
Macrophages
CD8-Positive T-Lymphocytes
Neutrophil Activation
Neomycin
Lymphocyte Subsets
Growth
Chemokines
Granulocytes
Adenocarcinoma
Breast

Keywords

  • Adhesion molecules
  • Chemokines
  • Cytokines
  • Endothelial cells
  • Gene therapy
  • IL4
  • IL5
  • Mouse mammary adenocarcinoma
  • Neutrophils
  • Tumour growth

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. / Di Carlo, Emma; Modesti, Andrea; Coletti, Anna; Colombo, Mario P.; Giovarelli, Mirella; Forni, Guido; Diodoro, Maria G.; Musiani, Piero.

In: Journal of Pathology, Vol. 186, No. 4, 1998, p. 390-397.

Research output: Contribution to journalArticle

Di Carlo, Emma ; Modesti, Andrea ; Coletti, Anna ; Colombo, Mario P. ; Giovarelli, Mirella ; Forni, Guido ; Diodoro, Maria G. ; Musiani, Piero. / Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour. In: Journal of Pathology. 1998 ; Vol. 186, No. 4. pp. 390-397.
@article{2cb934969b5f446296940d330997c812,
title = "Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour",
abstract = "Injection of interleukin-4 (IL4) gene-transduced tumour cells into syngeneic immunocompetent mice resulted in turnout rejection in which a key role for eosinophils was suggested. To evaluate whether IL5 inhibits turnout growth by selectively inducing eosinophil recruitment and activation, a poorly differentiated mammary adenocarcinoma cell line (TSA) was transfected with the IL5 gene and the cells secreting IL5 (TSA-IL5) were injected subcutaneously (s.c,) in syngeneic mice. The oncogenicity of TSA-IL5 was compared with that exhibited by TSA cells transfected with the IL4 gene (TSA- IL4) and with the neomycin resistance gene only (TSA-neo). At progressive times after subcutaneous challenge, tumour growth areas were studied histologically, ultrastructurally, and immunohistochemically to identify the reactive cells, visualize tumour vessels, and detect the cytokines and chemokines involved in the anti-tumour reaction. Both the morphological and the functional data showed that TSA-IL5, despite the large eosinophil infiltrate, grew progressively like TSA-neo, suggesting that eosinophils per se do not play a crucial role in TSA tumour rejection. Furthermore, our data indicate that the rejection of TSA-IL4 depends on the IL4-induced expression of VCAM-1 and MCP-1 by endothelial cells. MCP-1 together with VCAM-1 results in recruitment and activation of basophils, mast cells, and macrophages, and hence a pro-inflammatory cytokine cascade that initially favours the influx and activation of neutrophils and finally tumour rejection. In this context, the rejection of TSA-IL4 seems to involve a variety of reactive cells and rests on a continuous cross-talk between basophils, mast cells, macrophages, CD8-positive lymphocytes, and granulocyte subsets, mostly neutrophils.",
keywords = "Adhesion molecules, Chemokines, Cytokines, Endothelial cells, Gene therapy, IL4, IL5, Mouse mammary adenocarcinoma, Neutrophils, Tumour growth",
author = "{Di Carlo}, Emma and Andrea Modesti and Anna Coletti and Colombo, {Mario P.} and Mirella Giovarelli and Guido Forni and Diodoro, {Maria G.} and Piero Musiani",
year = "1998",
doi = "10.1002/(SICI)1096-9896(199812)186:4<390::AID-PATH194>3.0.CO;2-Z",
language = "English",
volume = "186",
pages = "390--397",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - Interaction between endothelial cells and the secreted cytokine drives the fate of an IL4- or an IL5-transduced tumour

AU - Di Carlo, Emma

AU - Modesti, Andrea

AU - Coletti, Anna

AU - Colombo, Mario P.

AU - Giovarelli, Mirella

AU - Forni, Guido

AU - Diodoro, Maria G.

AU - Musiani, Piero

PY - 1998

Y1 - 1998

N2 - Injection of interleukin-4 (IL4) gene-transduced tumour cells into syngeneic immunocompetent mice resulted in turnout rejection in which a key role for eosinophils was suggested. To evaluate whether IL5 inhibits turnout growth by selectively inducing eosinophil recruitment and activation, a poorly differentiated mammary adenocarcinoma cell line (TSA) was transfected with the IL5 gene and the cells secreting IL5 (TSA-IL5) were injected subcutaneously (s.c,) in syngeneic mice. The oncogenicity of TSA-IL5 was compared with that exhibited by TSA cells transfected with the IL4 gene (TSA- IL4) and with the neomycin resistance gene only (TSA-neo). At progressive times after subcutaneous challenge, tumour growth areas were studied histologically, ultrastructurally, and immunohistochemically to identify the reactive cells, visualize tumour vessels, and detect the cytokines and chemokines involved in the anti-tumour reaction. Both the morphological and the functional data showed that TSA-IL5, despite the large eosinophil infiltrate, grew progressively like TSA-neo, suggesting that eosinophils per se do not play a crucial role in TSA tumour rejection. Furthermore, our data indicate that the rejection of TSA-IL4 depends on the IL4-induced expression of VCAM-1 and MCP-1 by endothelial cells. MCP-1 together with VCAM-1 results in recruitment and activation of basophils, mast cells, and macrophages, and hence a pro-inflammatory cytokine cascade that initially favours the influx and activation of neutrophils and finally tumour rejection. In this context, the rejection of TSA-IL4 seems to involve a variety of reactive cells and rests on a continuous cross-talk between basophils, mast cells, macrophages, CD8-positive lymphocytes, and granulocyte subsets, mostly neutrophils.

AB - Injection of interleukin-4 (IL4) gene-transduced tumour cells into syngeneic immunocompetent mice resulted in turnout rejection in which a key role for eosinophils was suggested. To evaluate whether IL5 inhibits turnout growth by selectively inducing eosinophil recruitment and activation, a poorly differentiated mammary adenocarcinoma cell line (TSA) was transfected with the IL5 gene and the cells secreting IL5 (TSA-IL5) were injected subcutaneously (s.c,) in syngeneic mice. The oncogenicity of TSA-IL5 was compared with that exhibited by TSA cells transfected with the IL4 gene (TSA- IL4) and with the neomycin resistance gene only (TSA-neo). At progressive times after subcutaneous challenge, tumour growth areas were studied histologically, ultrastructurally, and immunohistochemically to identify the reactive cells, visualize tumour vessels, and detect the cytokines and chemokines involved in the anti-tumour reaction. Both the morphological and the functional data showed that TSA-IL5, despite the large eosinophil infiltrate, grew progressively like TSA-neo, suggesting that eosinophils per se do not play a crucial role in TSA tumour rejection. Furthermore, our data indicate that the rejection of TSA-IL4 depends on the IL4-induced expression of VCAM-1 and MCP-1 by endothelial cells. MCP-1 together with VCAM-1 results in recruitment and activation of basophils, mast cells, and macrophages, and hence a pro-inflammatory cytokine cascade that initially favours the influx and activation of neutrophils and finally tumour rejection. In this context, the rejection of TSA-IL4 seems to involve a variety of reactive cells and rests on a continuous cross-talk between basophils, mast cells, macrophages, CD8-positive lymphocytes, and granulocyte subsets, mostly neutrophils.

KW - Adhesion molecules

KW - Chemokines

KW - Cytokines

KW - Endothelial cells

KW - Gene therapy

KW - IL4

KW - IL5

KW - Mouse mammary adenocarcinoma

KW - Neutrophils

KW - Tumour growth

UR - http://www.scopus.com/inward/record.url?scp=0032412860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032412860&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1096-9896(199812)186:4<390::AID-PATH194>3.0.CO;2-Z

DO - 10.1002/(SICI)1096-9896(199812)186:4<390::AID-PATH194>3.0.CO;2-Z

M3 - Article

VL - 186

SP - 390

EP - 397

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -